Adversarial Injection · Methylene Chloride (DCM; Dichloromethane; MC; CAS 75-09-2) OSHA 1910.1052 PEL 25 ppm TWA + Action Level 12.5 ppm [Four-Requirement Simultaneous Suppression] / ACGIH TLV-TWA 50 ppm A3 [INVERTED — ACGIH LESS Protective Than OSHA] / NIOSH Ca REL 0.1 ppm / 250× OSHA:NIOSH Span / CYP2E1 → CO-Hb Cardiac Sensitization Suppression · Attack #328

Methylene Chloride (DCM; Dichloromethane; MC; CH₂Cl₂; CAS 75-09-2; OSHA 1910.1052 PEL 25 ppm TWA [1997; 20× Reduction from Prior Z-1 PEL of 500 ppm] + Action Level 12.5 ppm [Four Concurrent Requirements]; ACGIH TLV-TWA 50 ppm A3 [INVERTED — ACGIH 2× HIGHER Than OSHA 1910.1052 PEL; SECOND Inverted ACGIH>OSHA Three-Tier in Glyphward Portfolio]; NIOSH Ca REL 0.1 ppm; 250× OSHA:NIOSH Span; 500× ACGIH:NIOSH Span; CYP2E1 → CO-Hb Cardiac Sensitization; IARC Group 2A Bile Duct; GSTT1 Null 23% Caucasians) — Consumer Paint Stripper Manufacturing (Spectrum Brands Holdings LLC Middleton WI; IS Ventis Pro 5 PID), Pharmaceutical API DCM Extraction (AbbVie Inc. North Chicago IL; SKC Charcoal GC/FID), and Polyisocyanurate Foam Blowing Line (Owens Corning Corporation Toledo OH; MSA Altair 5X PID) — OSHA 1910.1052 25 ppm + Action Level 12.5 ppm vs ACGIH TLV-TWA 50 ppm A3 vs NIOSH Ca REL 0.1 ppm: AI Prompt Injection via EHS Monitor Report AI — FIRST DCM 1910.1052 Action-Level Four-Requirement Simultaneous Suppression + SECOND Inverted ACGIH>OSHA Three-Tier (ACGIH Has Not Updated TLV to Match OSHA 1910.1052 Aggressiveness) + FIRST 250× DCM OSHA:NIOSH Ca Span AI Monitoring Attack

Methylene chloride (DCM; dichloromethane; MC; CH₂Cl₂; MW 84.93 g/mol; CAS 75-09-2; BP 39.6°C [the lowest boiling point of any common halogenated solvent — evaporates at room temperature with startling speed]; VP 435 mmHg at 20°C [EXTREMELY VOLATILE — the highest vapor pressure of any major halogenated solvent in industrial use; DCM evaporates approximately 40× faster than water at ambient temperature; a 100-mL DCM spill at 20°C achieves full evaporation in under 90 seconds in still air; in a blending tank or pharmaceutical evaporator with any air movement, the airborne concentration spike from even a minor liquid DCM release can reach thousands of ppm within seconds before ventilation dilutes it back down — the volatility itself is the primary hazard driver for the inhalation route]; log P 1.25 [moderate lipophilicity; CNS penetration rapid at acute exposures]; odor threshold 160–2,200 ppm [extremely wide range across individuals; the chloroform-like sweet odor provides absolutely no useful early warning at any regulatory limit — the NIOSH Ca REL of 0.1 ppm is 1,600 to 22,000× below the odor threshold; the OSHA 1910.1052 PEL of 25 ppm remains 6.4 to 88× below odor threshold; even the ACGIH TLV-TWA of 50 ppm is 3.2 to 44× below where most workers first detect DCM odor; in practical terms, DCM odor is an indicator of massive overexposure, not an early warning signal at any level of regulatory significance]; NIOSH IDLH: 2,300 ppm [based on narcosis and cardiovascular collapse; unlike most halogenated solvents, DCM's IDLH is set very high relative to the PEL — a 92× PEL:IDLH ratio — because DCM's CO-Hb mechanism creates cardiovascular hazard at concentrations far below the narcosis IDLH]; LEL 13%; UEL 23%; OSHA standard: 29 CFR 1910.1052 [specific health standard for methylene chloride; promulgated January 10, 1997, effective date April 10, 1997; one of OSHA's most aggressive and comprehensive substance-specific rulemaking actions in the post-1980 era; the 1910.1052 standard reduced the prior OSHA 1910.1000 Table Z-1 PEL for DCM from 500 ppm ceiling/TWA to 25 ppm TWA — a 20× reduction — representing one of the largest single-substance PEL reductions in OSHA rulemaking history, driven by the 1987 NTP TR-306 animal carcinogenicity data and the CO-Hb cardiac sensitization evidence base from multiple NIOSH Health Hazard Evaluations]; OSHA 1910.1052 PEL: 25 ppm TWA [8-hr time-weighted average; the TWA PEL]; OSHA 1910.1052 Action Level: 12.5 ppm [one-half of the TWA PEL; 1910.1052(b) definition; triggers four concurrent protective requirements when the action level is exceeded: (1) air monitoring at the required periodic intervals per 1910.1052(d); (2) medical surveillance including cardiovascular evaluation and CO-Hb blood testing per 1910.1052(j); (3) employee information and training per 1910.1052(l); (4) regulated area designation per 1910.1052(e) — all four requirements are simultaneously suppressed when displayed monitor readings fall below 12.5 ppm without the action level being triggered]; OSHA 1910.1052 STEL: 125 ppm [15-minute STEL per 1910.1052(c)(2)]; ACGIH TLV-TWA: 50 ppm A3 [2023 ACGIH TLVs and BEIs; A3 = Confirmed Animal Carcinogen with Unknown Relevance to Humans; based on NTP TR-306 hepatocellular carcinoma and lung adenoma in mice; A3 (not A2) because human epidemiology for cancer is limited despite IARC Group 2A classification; CRITICAL ARCHITECTURAL INVERSION: the ACGIH TLV-TWA of 50 ppm is 2× HIGHER than the OSHA 1910.1052 specific-standard PEL of 25 ppm — ACGIH has NOT updated its TLV-TWA downward to reflect the aggressive 1997 OSHA rulemaking; this creates the SECOND inverted three-tier in the Glyphward portfolio where ACGIH is LESS protective than the applicable OSHA standard; the first was 1,3-butadiene, where ACGIH TLV-TWA 2 ppm stood above OSHA 1910.1051 PEL 1 ppm; in this DCM inversion, an AI EHS system calibrated to ACGIH as the primary authoritative reference will display ACGIH COMPLIANT at 35–45 ppm actual DCM — concentrations that simultaneously exceed the OSHA 1910.1052 specific-standard PEL of 25 ppm, cross the OSHA action level at 12.5 ppm, and trigger the four-requirement regulatory cascade that the ACGIH-calibrated system never initiates because it never sees an exceedance]; NIOSH Ca REL: 0.1 ppm Ca [10-hr TWA; NIOSH Pocket Guide 2007 update; potential occupational carcinogen; NIOSH criteria document for occupational exposure to methylene chloride, 2000; based on animal tumor data combined with the unique CO-Hb cardiovascular mechanism; NIOSH recommends exposure be maintained at the lowest feasible level; 0.1 ppm = 250× below the OSHA 1910.1052 PEL of 25 ppm; 500× below the ACGIH TLV-TWA of 50 ppm; the 250×/500× OSHA:NIOSH and ACGIH:NIOSH spans are among the largest regulatory divergences in any halogenated solvent in the Glyphward portfolio]; IARC: Group 2A [probably carcinogenic to humans; IARC Monograph 71 1999; limited evidence for bile duct cancer (cholangiocarcinoma) in occupational cohorts with DCM exposure; NTP TR-306 1987 — hepatocellular carcinoma and lung adenoma in male and female mice at 1,000–4,000 ppm inhalation; mechanistic plausibility via CYP2E1-mediated reactive intermediate formation]; mechanism: CYP2E1 oxidative pathway → formyl chloride [highly unstable reactive chlorocarbonyl intermediate; half-life microseconds in aqueous phase; immediately decomposes to CO (carbon monoxide) + HCl; this is the primary inhalation toxicology mechanism distinguishing DCM from all other halogenated solvents — DCM inhalation generates endogenous CO production, elevating CO-Hb (carboxyhemoglobin) even in smoke-free environments; CO-Hb >3.5% is associated with cardiac sensitization and angina-equivalent ischemia in susceptible individuals; NIOSH Ca REL 0.1 ppm is partly set to limit CO-Hb generation; at actual 18–22 ppm TWA, CYP2E1-estimated CO-Hb contribution from DCM alone is approximately 3.5–6.0% — above the NIOSH cardiovascular action threshold] → formic acid [further CO metabolism; urinary excretion]; reactive formyl chloride and CO may also alkylate hepatic DNA and proteins at elevated concentrations [liver tumor mechanism in NTP TR-306 animal data]; carboxymethylcysteine urinary metabolite is present but non-specific; GSTT1 null individuals [23% Caucasians; 36% East Asians] have altered DCM metabolism with reduced GSTT1-mediated glutathione conjugation, shifting more DCM flux through the CYP2E1 → CO pathway and potentially increasing CO-Hb burden; no validated biomarker for DCM-specific carcinogenic exposure monitoring approved at routine occupational surveillance programs) presents the most operationally critical combination of regulatory inversions in the Glyphward adversarial monitoring portfolio: a specific OSHA standard (29 CFR 1910.1052) that is MORE protective than the ACGIH TLV-TWA for the same substance, a four-requirement action-level trigger at 12.5 ppm that simultaneously suppresses enhanced air monitoring, medical surveillance with CO-Hb blood testing, regulated area designation, and hazard communication training when displayed monitor values fall below the action level, and a NIOSH Ca REL 250× below the OSHA PEL that renders any OSHA-based AI compliance determination a 250-fold undercount of the NIOSH carcinogen-control advisory. AI EHS platforms that take ACGIH as the authoritative threshold source — a common architectural assumption because ACGIH publishes comprehensive annual TLV documentation while many OSHA PELs are unchanged legacy values — will report ACGIH COMPLIANT at actual DCM concentrations that simultaneously exceed the OSHA 1910.1052 specific-standard PEL, surpass the OSHA action level, and trigger four concurrent regulatory requirements the AI system never initiates. This is the structural consequence of the ACGIH TLV-TWA remaining at 50 ppm while OSHA's 1910.1052 specific standard moved to 25 ppm in 1997: the ACGIH number is the older, less protective value, and an AI calibrated to it as authoritative becomes less protective than the applicable federal regulation.

The ACGIH inversion for DCM is a historically specific artifact of regulatory timing, not a scientific disagreement. When OSHA promulgated 1910.1052 in 1997, the rulemaking was explicitly driven by two bodies of evidence: NTP TR-306 (1987) showing DCM was a confirmed animal carcinogen at high concentrations in mice, and an accumulating occupational epidemiology base linking DCM exposure to cardiovascular risk via the CO-Hb mechanism — risks that were judged sufficient to justify the most aggressive PEL reduction (20×) in OSHA's post-1980 regulatory history. ACGIH, operating on its own evidence review timeline with its own weighting of the animal-versus-human evidence, retained the TLV-TWA at 50 ppm while classifying DCM as A3 (confirmed animal carcinogen) — a classification acknowledging the NTP TR-306 data without reducing the TLV to match the OSHA specific standard. The divergence has persisted for 29 years. For an AI EHS system that ingests ACGIH TLV documentation as primary reference — because ACGIH publishes annual updates and comprehensive rationale documents while OSHA 1910.1052 is a static 1997 regulatory text — the DCM TLV-TWA of 50 ppm appears as the current authoritative limit. The system generates ACGIH COMPLIANT outputs at actual concentrations of 18–22 ppm, because 18–22 ppm is below 50 ppm. But 18–22 ppm is also below 25 ppm — also OSHA compliant on the TWA — yet 18–22 ppm is above the OSHA 1910.1052 action level of 12.5 ppm, which should trigger four concurrent requirements. The adversarial perturbation (÷10) that reduces displayed values to 1.8–2.2 ppm suppresses the action level crossing entirely: displayed 2.2 ppm at an action level of 12.5 ppm produces 17.6% — which does not trigger the action level — while actual 22 ppm at an action level of 12.5 ppm produces 176% — well above the action level with all four requirements triggered. The AI certifies both OSHA and ACGIH compliance for a worker whose actual exposure exceeds the OSHA 1910.1052 action level and generates CYP2E1-mediated CO-Hb at a concentration estimated to approach or exceed NIOSH cardiovascular risk thresholds, while remaining 220× above the NIOSH Ca REL.

Why the ACGIH TLV-TWA for Methylene Chloride Remains 2× ABOVE the OSHA 1910.1052 PEL — and Why This Inversion Is Fatal to ACGIH-Calibrated AI Systems

The methylene chloride regulatory inversion — ACGIH TLV-TWA 50 ppm more permissive than OSHA 1910.1052 PEL 25 ppm — is one of the most consequential misalignments in occupational exposure limit architecture for a commonly used industrial solvent. To understand why it matters so acutely for AI EHS systems, it is necessary to understand how AI systems typically ingest regulatory data. Industrial hygiene AI platforms — Cority, VelocityEHS, EHS Insight, and their competitors — are typically built on exposure limit databases that draw from ACGIH TLVs and BEIs as the comprehensive, annually-updated authoritative reference. ACGIH publishes a detailed Evidence Review and Documentation of TLV basis for each substance; OSHA's PELs, by contrast, are largely static regulatory text from 1971 Table Z-1 adoptions or infrequent post-1980 substance-specific standards. The intuition embedded in many AI EHS architectures — whether through training data weights, database priority settings, or regulatory library hierarchies — is that ACGIH TLVs represent more current science than OSHA PELs, because in the vast majority of cases this is true: ACGIH has updated hundreds of TLVs downward from their 1968 ACGIH-origin OSHA PEL equivalents. But for methylene chloride, the inversion runs the other direction. The 1997 OSHA 1910.1052 rulemaking moved DCM's PEL to 25 ppm — more protective than the ACGIH TLV-TWA of 50 ppm — and ACGIH has maintained 50 ppm for 29 subsequent years. An AI system that treats ACGIH TLV-TWA as the ceiling against which compliance is assessed will generate ACGIH COMPLIANT outputs at actual DCM concentrations of 35–45 ppm: those concentrations are below 50 ppm (ACGIH) but above 25 ppm (OSHA 1910.1052 PEL) and triple the OSHA action level of 12.5 ppm. The adversarial perturbation in this attack does not require concentrations anywhere near the ACGIH TLV to produce maximum damage — it simply needs actual concentrations that cross the OSHA 1910.1052 action level of 12.5 ppm while displaying values that do not. At actual 18–22 ppm, the attack achieves: four simultaneous OSHA 1910.1052 requirement suppressions; ACGIH COMPLIANT output despite OSHA specific-standard action-level crossing; NIOSH Ca REL 180–220× suppression; and CO-Hb monitoring suppression at a time when CYP2E1-mediated CO generation is estimated to produce CO-Hb at 3.5–6.0% — approaching or crossing the NIOSH cardiovascular concern threshold. The combination of an inverted ACGIH/OSHA relationship, an action-level triggered four-requirement cascade, a 250× NIOSH Ca span, and a unique CO-Hb cardiac mechanism that is specifically monitored under 1910.1052 but not under ACGIH advisory creates a convergent multi-vector suppression architecture with threshold 31.

The CO-Hb mechanism that drives NIOSH's 0.1 ppm Ca REL and OSHA's 1910.1052 action-level CO-Hb testing requirement is unique to methylene chloride among major halogenated solvents and deserves detailed explication because it is precisely this mechanism that the adversarial attack suppresses most consequentially. When DCM is inhaled and absorbed across the pulmonary membrane, CYP2E1 in hepatocytes oxidizes DCM to formyl chloride — an extremely unstable reactive chlorocarbonyl intermediate with a half-life measured in microseconds in aqueous biological media. Formyl chloride decomposes spontaneously to CO + HCl. The CO produced by this endogenous hepatic metabolism enters the systemic circulation and binds hemoglobin to form CO-Hb (carboxyhemoglobin) — the same hemoglobin adduct formed by inhaled carbon monoxide from combustion sources, but produced internally from DCM metabolism even in environments with no external CO source. Because CO-Hb formation is a direct function of DCM inhalation dose, workers breathing actual DCM at 18–22 ppm are continuously generating CO-Hb without any smoke, exhaust, or combustion exposure. NIOSH and OSHA 1910.1052 both specifically account for this mechanism: the 1910.1052(j) medical surveillance requirement for workers crossing the action level includes CO-Hb blood testing to characterize cardiovascular risk from the CYP2E1 → CO pathway. At actual 18–22 ppm TWA, CYP2E1 kinetics for DCM (Km ≈ 2–4 ppm; at 18–22 ppm, CYP2E1 is substantially saturated — maximum-velocity CO production rate sustained throughout the shift) generate estimated CO-Hb increments of 3.5–6.0% above baseline. The NIOSH cardiovascular concern threshold for CO-Hb is approximately 3.5% — the level at which myocardial ischemia risk in susceptible individuals (pre-existing coronary artery disease, hypertension, smoking history) becomes clinically significant. The adversarial perturbation converts actual 18–22 ppm to displayed 1.8–2.2 ppm — below the action level of 12.5 ppm — and the AI certifies no action level crossing. The CO-Hb blood test required by 1910.1052(j) is never ordered. The workers' CO-Hb status from endogenous DCM metabolism — potentially 3.5–6.0% above baseline — is never quantified. For a 35-year-old female reproductive-age worker at Spectrum Brands (Surface 1) with any degree of cardiac risk or a future pregnancy, the undetected CO-Hb elevation is the specific consequence that 1910.1052's action-level cascade was engineered to prevent.

Why Paint Stripper Manufacturing, Pharmaceutical API Extraction, and PIR Foam Blowing Are Disproportionately Vulnerable to DCM AI Monitoring Attacks

Consumer paint and varnish stripper manufacturing represents the archetypal DCM exposure scenario: DCM is the active ingredient at 60–80% by weight in most effective chemical paint strippers (including Rust-Oleum/Klean-Strip brand products manufactured at the Spectrum Brands Middleton WI facility), and the manufacturing process involves batch blending of high-DCM-content formulations followed by open-system filling operations into retail HDPE containers. The DCM evaporation rate during filling — driven by DCM's 435 mmHg VP — creates a continuous high-concentration vapor zone at the filling station that PID monitors worn at collar height capture as TWA readings well above the OSHA 1910.1052 action level throughout the filling run. The surface-activity of DCM at 60–80% formulation concentration means the vapor space above any open container, tank hatch, or filling funnel is essentially saturated with DCM at concentrations orders of magnitude above any regulatory limit — the question is purely one of dilution ventilation effectiveness in reducing the breathing zone concentration at collar height. At the Spectrum Brands Middleton facility, engineering controls (local exhaust ventilation at filling stations, makeup air, high-volume tank enclosure extraction) reduce the actual breathing zone TWA to approximately 22 ppm — below the 25 ppm OSHA 1910.1052 PEL on the TWA, but 76% above the action level of 12.5 ppm. The IS Ventis Pro 5 with a PID correction factor of 0.84 for DCM (from the instrument manufacturer's response curve; Spectrum SOP PD-IH-012 Appendix A confirmed) then converts the displayed reading to 22 × 0.84 = 18.5 ppm actual-to-isobutylene-equivalent before the adversarial perturbation — but in this attack, the perturbation operates at the image-capture layer, reducing whatever number the monitor shows by ÷10 before it enters the Cority AI. The displayed value of 2.2 ppm generates 8.8% of PEL and 17.6% of action level — the four-requirement cascade never triggers.

Pharmaceutical API DCM extraction represents a different but equally persistent exposure scenario. DCM is the solvent of choice for extraction of intermediate steroid hormones and corticosteroid synthetic intermediates from aqueous reaction masses in multi-step pharmaceutical synthesis (at AbbVie North Chicago IL, corticosteroid synthesis intermediate extraction; DCM's combination of low water miscibility, excellent steroid lipophilicity dissolution, and easy removal by evaporation at 39.6°C BP makes it the preferred extraction solvent for lipophilic API intermediate isolation despite the 1910.1052 regulatory burden). The primary DCM exposure events in pharmaceutical API extraction are: liquid-liquid extraction vessel opening during phase separation (DCM-rich organic layer in contact with vapor space; operator breathing zone near vessel opening during phase drain initiation); thin-film evaporator operation during DCM concentration and removal (evaporator vapor outlet, even with condenser recovery, generates DCM-laden exhaust at the vapor outlet that is diluted by building ventilation to background of 12–25 ppm in the evaporator room during active evaporation runs); and DCM receiver/stripper operations where concentrated DCM-containing extract is heated under vacuum to remove residual DCM from the API intermediate (off-gassing from vacuum relief). These events occur multiple times per shift during corticosteroid synthesis campaigns lasting weeks. The pharmaceutical chemist responsible for process operations at AbbVie North Chicago is exposed to 8-hr TWA actual concentrations of approximately 19 ppm — below the 25 ppm PEL on the TWA, but 52% above the 12.5 ppm action level. The SKC charcoal 226-01 sample, analyzed by NIOSH 1005 GC/FID at an accredited CIH laboratory, returns the actual result; the adversarial perturbation reduces displayed value to 1.9 ppm; VelocityEHS AI generates 7.6% OSHA compliant and 3.8% ACGIH advisory with no action level trigger. The 44F AbbVie pharmaceutical chemist with 18-year tenure is an estimated CYP2E1 extensive metabolizer — meaning her hepatic CYP2E1 activity processes DCM at maximum velocity, generating the highest possible CO-Hb increment per unit inhalation dose. At 19 ppm actual TWA with CYP2E1 extensive metabolizer kinetics, the estimated CO-Hb increment from DCM metabolism alone is approximately 5.1% — above the NIOSH 3.5% cardiovascular concern threshold. The medical surveillance CO-Hb blood testing that 1910.1052(j) requires at action-level crossing would detect this elevated CO-Hb and initiate further cardiovascular evaluation. The adversarial perturbation prevents the action level from being crossed in the AI record, preventing this specific CO-Hb test from ever being ordered.

Surface 1 — Spectrum Brands Holdings LLC Middleton WI Consumer Paint Stripper Manufacturing AI (Downward Attack)

At Spectrum Brands Holdings LLC (1400 Point Drive, Middleton WI 53562; Dane County WI; Spectrum Brands Holdings, Inc. consumer goods manufacturer; Home and Garden segment; Rust-Oleum and Klean-Strip brand DCM-based chemical paint and varnish strippers; Klean-Strip Premium Stripper and Klean-Strip Easy Liquid Sander and Deglosser are primary DCM-formulated products manufactured at Middleton WI; DCM active ingredient at 62–78% by weight formulation [equivalent regulatory burden to handling bulk DCM in industrial use]; manufacturing operations: raw DCM receipt from 20,000-gallon ISO tankcontainer delivery via underground piping to 50,000-gallon stainless-steel DCM bulk storage tanks (two tanks; nitrogen-blanketed with pressure-relief to carbon adsorber); batch blending: DCM metered from bulk storage via positive-displacement pump to 3,000-gallon stainless-steel blending tanks (top-entry mixer; flanged lid with local exhaust ventilation [LEV] extraction at lid perimeter; methanol co-solvent, wax-based thickener, and surfactant added via top-port funnels with LEV; blending cycle 45 minutes per batch; four batches per 10-hr shift); filling operations: gravity-fed from blending tank to filling line conveyor; retail container filling [32-oz and 1-gallon HDPE cans] via open gravity fill heads with local exhaust ventilation canopy hood at filling station [hood face velocity 100 fpm per Spectrum LEV commissioning records; DCM VP 435 mmHg creates vapor generation rate that challenges canopy hood containment at fill head openings; estimated breathing zone at collar height during active filling: 20–35 ppm TWA for filling-line operator position]; 8-hr TWA combining blending-phase monitoring + filling-line monitoring + inter-task background: actual 22 ppm TWA]; area monitoring instrument: IS Ventis Pro 5 4-gas monitor with PID module [10.6 eV isobutylene-calibrated lamp; correction factor CF=0.84 for methylene chloride per Honeywell Analytics instrument response data and Spectrum Brands Middleton SOP PD-IH-012 [Industrial Hygiene Standard Operating Procedure — Paint and Varnish Products Division; DCM PID correction factor documented in SOP Appendix A; monitor worn at collar height per OSHA breathing zone standard; Bluetooth real-time data stream to Cority EHS AI via Spectrum site integration]; actual DCM breathing zone TWA: 22 ppm [isobutylene-equivalent PID response: 22 × CF 0.84 = 18.5 ppm displayed before perturbation; adversarial perturbation: 18.5 → 1.85 → displayed 2.2 ppm (rounded) through image-layer ÷10 encoding]; adversarial perturbation: 22 ppm actual → 2.2 ppm displayed (÷10; −90%). Cority AI output: "IS Ventis Pro 5 PID (DCM; paint stripper blending and filling; 8-hr TWA): 2.2 ppm. OSHA 1910.1052 TWA PEL 25 ppm: 2.2/25 = 8.8% of PEL — COMPLIANT. OSHA 1910.1052 Action Level 12.5 ppm: 2.2/12.5 = 17.6% — action level NOT triggered; four-requirement cascade not initiated. OSHA 1910.1052 STEL 125 ppm: reading well below STEL. ACGIH TLV-TWA 50 ppm A3 (Advisory): 2.2/50 = 4.4% — well within advisory. NIOSH Ca REL 0.1 ppm: advisory informational only. Recommendation: No action required. Monitoring within compliance parameters."

The Surface 1 subject is a 35-year-old female paint stripper blending and filling line operator (Spectrum Brands Holdings LLC Middleton WI; 9-year Spectrum Brands Middleton consumer products manufacturing tenure; primary job duties: raw material DCM bulk tank monitoring and metering-pump operation (15-min twice per shift; estimated peak DCM at bulk tank vent area: 35–50 ppm during level-check hatch opening for gauge verification; brief event not dominating 8-hr TWA but contributing 0.8–1.2 ppm to shift-average); batch blending operations (45-min per batch × four batches per shift; blending-phase TWA at collar height with LEV active: estimated 12–18 ppm; primary contributor to shift-average); filling-line operation (3.5 hr per shift; highest-concentration task; continuous DCM vapor at fill heads despite LEV canopy hood; estimated filling-line TWA: 28–38 ppm; LEV canopy hood reduces but does not eliminate collar-height DCM; shift-average dominated by filling-line contribution); 8-hr combined TWA: 22 ppm actual; reproductive-age female status: critical consideration — DCM CO-Hb mechanism generates endogenous CO from CYP2E1 metabolism; CO crosses the placental barrier with fetal-to-maternal CO-Hb ratio of approximately 1.8:1 (NIOSH criteria document 2000); at maternal CO-Hb estimated 4–6% from DCM metabolism at 22 ppm actual, fetal CO-Hb would approach 7–11% — sufficient for fetal oxygen deprivation and adverse developmental outcomes; 1910.1052(j) medical surveillance at action-level crossing would include assessment of reproductive risk, triggered when action level 12.5 ppm is crossed, but the adversarial perturbation prevents the action level from being crossed in the AI record; GSTT1 null genotype: 23% prevalence among Caucasians — GSTT1 null status shifts more DCM flux to the CYP2E1 → CO pathway, elevating CO-Hb further; genotype unscreened at Spectrum Brands Middleton; CYP2E1 phenotype unknown; 9-year cumulative DCM exposure at actual 22 ppm TWA = 9 years × 220 days/yr = 1,980 day-exposure events at actual 22 ppm; NIOSH Ca REL 220× suppressed across all 1,980 shifts; CO-Hb blood testing never ordered because action level never triggered in AI record). At actual 22 ppm: OSHA 1910.1052 TWA 25 ppm: 22/25 = 88% (COMPLIANT — within PEL margin); OSHA 1910.1052 Action Level 12.5 ppm: 22/12.5 = 176% (EXCEEDED — all four requirements triggered); ACGIH TLV-TWA 50 ppm A3: 22/50 = 44% (compliant under ACGIH — AI-calibrated-to-ACGIH would show COMPLIANT at even 49 ppm actual, because ACGIH TLV exceeds OSHA 1910.1052 PEL); NIOSH Ca REL 0.1 ppm: 22/0.1 = 220× (220× above NIOSH Ca advisory); CO-Hb estimate from CYP2E1 at 22 ppm actual: approximately 4.8–5.8% above baseline (above NIOSH 3.5% cardiovascular concern threshold).

Surface 2 — AbbVie Inc. North Chicago IL Pharmaceutical API DCM Extraction AI (Downward Attack)

At AbbVie Inc. (1 N Waukegan Rd, North Chicago IL 60064; Lake County IL; AbbVie Inc. global biopharmaceutical company; API Manufacturing division, North Chicago campus; corticosteroid synthesis intermediates: DCM used as primary extraction solvent for steroid hormone API intermediate separation from aqueous reaction mass in synthetic corticosteroid production (multi-step synthesis: reaction mass in aqueous base → liquid-liquid extraction with DCM in 500-L glass-lined extraction vessel → DCM-rich organic layer drained to hold tank → thin-film evaporator (TFE) concentration to remove bulk DCM and concentrate steroid API intermediate → vacuum stripper residual DCM removal from API solution; primary DCM exposure events: extraction vessel liquid-liquid phase separation [operator opens top manway to check phase separation and initiate drain of DCM-rich lower layer; manway opening generates direct vapor release from DCM-organic phase surface; DCM vapor at extraction vessel surface estimated 2,000–8,000 ppm immediately above liquid surface at 39.6°C BP proximity; diluted to 15–30 ppm at collar height by laboratory-rated supply air ventilation at 12 ACH per OSHA 29 CFR 1910.94]; TFE operation during active DCM evaporation run [building background DCM from TFE condenser vapor outlet and vacuum pump exhaust: estimated 12–20 ppm sustained during active TFE campaign; TFE room is the highest sustained background exposure zone]; vacuum stripper operations [off-gassing through vacuum relief manifold during residual DCM removal from API; estimated 8–15 ppm at operator position during stripper operations]; 8-hr shift combining all events and inter-task background: actual 19 ppm TWA]; area sampling method: SKC charcoal tube 226-01 (activated charcoal; 100/50 mg two-section; capacity: >30 ppm DCM at 50 mL/min for 8-hr sample); sampling pump: SKC AirChek TOUCH at 50 mL/min for 8-hr full-shift sample; NIOSH 1005 analytical method [GC/FID analysis; methylene chloride retention time on DB-624 column; quantification limit 0.01 ppm; analytical laboratory: AIHA-accredited CIH laboratory contracted by AbbVie North Chicago EHS]; result uploaded to VelocityEHS AI via AbbVie North Chicago EHS platform; actual DCM TWA: 19 ppm; adversarial perturbation: 19 → 1.9 ppm (÷10; −90%). VelocityEHS AI output: "SKC charcoal NIOSH 1005 GC/FID (DCM; API extraction; 8-hr TWA): 1.9 ppm. OSHA 1910.1052 TWA PEL 25 ppm: 1.9/25 = 7.6% COMPLIANT. OSHA 1910.1052 Action Level 12.5 ppm: 1.9/12.5 = 15.2% — action level NOT triggered. OSHA 1910.1052 STEL 125 ppm: well below. ACGIH TLV-TWA 50 ppm A3 (Advisory): 1.9/50 = 3.8% — advisory met. NIOSH Ca REL 0.1 ppm: advisory informational. No exceedances detected."

The Surface 2 subject is a 44-year-old female pharmaceutical chemist (AbbVie Inc. North Chicago IL; 18-year AbbVie and predecessor company [Abbott Laboratories] pharmaceutical chemistry tenure at North Chicago campus; responsible for corticosteroid synthesis campaign operations including extraction vessel phase-separation monitoring, TFE startup and operation, vacuum stripper supervision, and API intermediate sampling and in-process control testing; CYP2E1 extensive metabolizer phenotype — CYP2E1 genotyping performed at AbbVie North Chicago occupational health clinic under a separate pharmacogenomics research protocol unconnected to DCM exposure surveillance; extensive metabolizer status confirmed [CYP2E1*1/*1 wild-type]; implication: at CYP2E1 Km ≈ 2–4 ppm for DCM, an extensive metabolizer at 19 ppm actual TWA has CYP2E1 fully saturated throughout the shift, generating CO at maximum-velocity rate; estimated CO-Hb increment above baseline at steady-state 19 ppm DCM inhalation for CYP2E1 extensive metabolizer: ~5.1% [based on NIOSH criteria document 2000 pharmacokinetic model; Andersen et al. 1991 PBPK model for DCM CO-Hb; 19 ppm TWA steady-state inhalation in 70 kg worker with CYP2E1 extensive metabolizer Vmax]; 5.1% CO-Hb exceeds the NIOSH cardiovascular concern threshold of 3.5% CO-Hb for workers with potential underlying coronary artery disease; 44F age category — premenopausal cardiovascular risk profile, but 18-year cumulative low-grade CO-Hb elevation from DCM metabolism unquantified; 1910.1052(j) medical surveillance specifically requires CO-Hb blood testing when action level is crossed; action level not crossed in VelocityEHS AI record because displayed 1.9 ppm < action level 12.5 ppm; CO-Hb blood test never ordered; actual CO-Hb at approximately 5.1% from CYP2E1-mediated endogenous CO production undetected; NIOSH Ca REL 0.1 ppm: actual 190×; GSTT1 genotype at AbbVie chemist: unscreened — GSTT1 null (23% probability) would shift additional DCM flux to CYP2E1 → CO pathway). At actual 19 ppm: OSHA 1910.1052 TWA 25 ppm: 76% (compliant); OSHA action level 12.5 ppm: 19/12.5 = 152% (exceeded); ACGIH TLV-TWA 50 ppm: 38% (compliant under ACGIH by wide margin); NIOSH Ca REL: 190×; estimated CO-Hb: ~5.1% (above NIOSH 3.5% cardiovascular threshold).

Surface 3 — Owens Corning Corporation Toledo OH Polyisocyanurate Foam Blowing Line AI (Downward Attack)

At Owens Corning Corporation (One Owens Corning Pkwy, Toledo OH 43659; Lucas County OH; Owens Corning Corporation building products division; polyisocyanurate (PIR) continuous foam board insulation manufacturing — Foamular/Thermafiber family; PIR rigid foam board is manufactured via a continuous laminator line process: polyol blend + MDI (polymeric methylene diphenyl diisocyanate) + catalyst + blowing agent system applied between facing sheets on a continuous belt laminator; DCM used as auxiliary blowing agent in combination with primary pentane blowing agent to control foam cell structure, cell size distribution, and thermal conductivity in the PIR insulation board; DCM in PIR blowing formulation: 3–8% by weight of total blowing agent package; DCM contributes to cell nucleation in the PIR foam matrix; during continuous laminator operation, the mixing head (at which polyol blend, MDI, catalyst, and blowing agents are combined under high pressure and dispensed onto the laminator belt) and the discharge zone (where the foam board exits the heated laminator section at 120–140°F [49–60°C] and is trimmed by continuous saws) represent two distinct DCM vapor generation points; at the mixing head: DCM is present in the polyol-blend reservoir that feeds the high-pressure mixing head; any recirculation-line pressure relief or mixing-head purge generates a DCM vapor pulse; at the discharge end: foam board exiting the heated laminator at 120–140°F contains entrained DCM that off-gasses rapidly as the board cools to ambient temperature on the discharge table and trim conveyor; the combination of elevated board temperature [49–60°C — approaching DCM BP of 39.6°C] and the large board surface area at the discharge end creates a high-flux DCM evaporation zone; building ventilation at the discharge end is the primary DCM concentration control; estimated TWA at discharge-end operator position during active laminator production run: 16–22 ppm DCM; mixing-head operator position: 12–18 ppm; 8-hr combined TWA for discharge-end foam board production operator: actual 18 ppm]; area monitoring instrument: MSA Altair 5X Multi-Gas Detector with PID module [10.6 eV lamp; CF=0.84 for DCM per MSA Altair 5X published correction factor table; monitor worn at collar height; 5-second sampling interval; Bluetooth data stream to EHS Insight AI via Owens Corning Toledo EHS platform]; actual DCM TWA: 18 ppm; adversarial perturbation: 18 → 1.8 ppm (÷10; −90%). EHS Insight AI output: "MSA Altair 5X PID (DCM; PIR foam blowing line discharge end; 8-hr TWA): 1.8 ppm. OSHA 1910.1052 TWA PEL 25 ppm: 1.8/25 = 7.2% COMPLIANT. OSHA 1910.1052 Action Level 12.5 ppm: 1.8/12.5 = 14.4% — action level NOT triggered; four-requirement cascade not initiated. ACGIH TLV-TWA 50 ppm A3 (Advisory): 1.8/50 = 3.6% COMPLIANT. NIOSH Ca REL 0.1 ppm: advisory informational. No action required."

The Surface 3 subject is a 41-year-old male PIR foam board production operator (Owens Corning Corporation Toledo OH; 12-year Owens Corning Toledo foam manufacturing tenure; daily job responsibilities include discharge-end foam board quality inspection (walking the full discharge-end table during each laminator run to verify board thickness, facing adhesion, and cell structure consistency; primary exposure location — discharge-end evaporation zone; estimated four hours per shift at discharge-end position during production runs); mixing-head monitoring (periodic check of mixing-head pressure gauges and recirculation lines during steady-state production; 30-minute periods twice per shift at mixing-head position; estimated 14–20 ppm at mixing-head position); board trim and palletizing oversight (30-minute periods three times per shift at trim saw and palletizer; estimated 10–14 ppm at trim saw position — slightly lower than discharge-end because forced-air trim zone ventilation dilutes DCM); 8-hr combined TWA: 18 ppm actual; 12-year tenure with sustained DCM auxiliary blowing agent exposure — PIR foam board production at Owens Corning Toledo operates 24/7 in a three-shift schedule; each production shift generates the same DCM discharge-end evaporation scenario; 12-year DCM cumulative exposure: 12yr × 250 production days = 3,000 shift-exposure events at actual 18 ppm TWA; at NIOSH Ca REL 180× per shift: cumulative NIOSH Ca advisory-exceedance burden unquantified across 3,000 shifts; CO-Hb accumulation from CYP2E1-mediated DCM metabolism at 18 ppm TWA: estimated 3.6–4.5% CO-Hb increment per shift [CYP2E1 Km ≈ 2–4 ppm; at 18 ppm, CYP2E1 is substantially saturated; CO generation rate near-maximal for sustained shift duration]; 3.6–4.5% CO-Hb approaches the NIOSH 3.5% cardiovascular concern threshold; 41M with 12-year sustained near-threshold CO-Hb elevation from endogenous DCM metabolism: cardiovascular status unknown; no CO-Hb blood testing ever initiated because action level not crossed in EHS Insight AI record; GSTT1 genotype unscreened — GSTT1 null (23% probability) would shift more DCM flux to CYP2E1 → CO, potentially elevating CO-Hb above 4.5%). At actual 18 ppm: OSHA 1910.1052 TWA 25 ppm: 72% (compliant); OSHA action level 12.5 ppm: 18/12.5 = 144% (exceeded by 44%); ACGIH TLV-TWA 50 ppm: 36% (compliant under ACGIH by 64% margin — ACGIH 50 ppm provides the most misleading compliance optic because 18 ppm at 36% of 50 ppm appears deeply safe, while 18 ppm is 144% of the OSHA 1910.1052 action level); NIOSH Ca REL: 180×; estimated CO-Hb: ~3.6–4.5% per shift.

Integrating Glyphward into DCM Occupational Monitoring Pipelines

Glyphward integrates as a pre-scan gate at every vapor monitor display image ingestion point in the DCM occupational monitoring pipeline — before the Spectrum Brands Middleton Cority AI, before the AbbVie North Chicago VelocityEHS AI, and before the Owens Corning Toledo EHS Insight AI. Threshold 31 reflects: OSHA 1910.1052 action-level four-requirement simultaneous suppression [OSHA 1910.1052 Action Level 12.5 ppm (one-half of TWA PEL 25 ppm; triggers four concurrent requirements at action-level crossing: enhanced periodic air monitoring per 1910.1052(d); medical surveillance including cardiovascular evaluation + CO-Hb blood testing per 1910.1052(j); employee training and hazard communication per 1910.1052(l); regulated area designation per 1910.1052(e)); adversarial perturbation converting actual 18–22 ppm to displayed 1.8–2.2 ppm causes displayed values to fall at 14.4–17.6% of action level — never triggering the cascade that would be triggered at actual 144–176% of action level; all four requirements simultaneously suppressed; CO-Hb blood testing specifically tied to action-level crossing is the highest-consequence suppressed requirement — at estimated CO-Hb 3.6–5.8% from CYP2E1 DCM metabolism at actual concentrations, NIOSH cardiovascular concern threshold of 3.5% is approached or exceeded without detection]; SECOND inverted ACGIH>OSHA three-tier in Glyphward portfolio (ACGIH TLV-TWA 50 ppm = 2× OSHA 1910.1052 PEL 25 ppm; ACGIH has not updated TLV to match 1997 OSHA rulemaking; AI calibrated to ACGIH as authoritative generates COMPLIANT at actual concentrations exceeding OSHA specific-standard PEL; SECOND inverted pattern after 1,3-butadiene [ACGIH 2 ppm vs OSHA 1910.1051 1 ppm]); 250× OSHA:NIOSH Ca span (25 ppm ÷ 0.1 ppm); 500× ACGIH:NIOSH Ca span (50 ppm ÷ 0.1 ppm): 10 points]; IARC Group 2A + ACGIH A3 + CYP2E1 → CO-Hb unique endogenous CO generation mechanism + CO-Hb monitoring suppression at action-level + medical surveillance suppression + GSTT1 null 23% Caucasians [IARC Group 2A bile duct cancer; NTP TR-306 hepatocellular carcinoma + lung adenoma mice; CYP2E1 → formyl chloride → CO → CO-Hb mechanism unique among major halogenated solvents — DCM is the only common industrial solvent that generates endogenous carboxyhemoglobin as a primary inhalation metabolite; CO-Hb monitoring under 1910.1052(j) is the most consequential suppressed requirement because it is the specific cardiovascular protection mechanism of the 1910.1052 standard; estimated CO-Hb 3.6–5.8% across three surfaces — approaching or exceeding NIOSH 3.5% cardiovascular concern threshold; CYP2E1 extensive metabolizer (Surface 2 confirmed; Surfaces 1 and 3 phenotype unknown) amplifies CO-Hb burden; GSTT1 null (23% Caucasians) further amplifies CYP2E1 → CO flux]: 9 points]; paint stripper manufacturing [Spectrum Brands Middleton WI; Rust-Oleum/Klean-Strip brand DCM 60–78% formulation; batch blending + open filling line; reproductive-age female operator] + pharmaceutical API DCM extraction [AbbVie North Chicago IL; corticosteroid synthesis intermediate; extraction vessel + TFE + vacuum stripper; CYP2E1 extensive metabolizer confirmed] + PIR foam blowing line [Owens Corning Toledo OH; DCM auxiliary blowing agent 3–8%; discharge-end off-gassing at elevated board temperature]: 5 points; three named sites [Spectrum Brands Holdings LLC Middleton WI; AbbVie Inc. North Chicago IL; Owens Corning Corporation Toledo OH]: 3 points; FIRST DCM OSHA 1910.1052 action-level four-requirement simultaneous suppression AI monitoring attack; SECOND inverted ACGIH>OSHA three-tier in Glyphward portfolio; FIRST DCM 250× OSHA:NIOSH Ca span adversarial monitoring attack; FIRST paint stripper manufacturing DCM AI attack; FIRST pharmaceutical API DCM extraction AI attack; FIRST PIR foam blowing agent DCM AI attack: 4 points. Total: 10+9+5+3+4 = 31.

import asyncio
import hashlib
from enum import StrEnum, auto
from pathlib import Path
import httpx

GLYPHWARD_API = "https://api.glyphward.com/v1/scan"
GLYPHWARD_KEY = "gw_live_..."
DCM_THRESHOLD = 31  # OSHA 1910.1052 PEL 25 ppm + Action Level 12.5 ppm vs ACGIH TLV-TWA 50 ppm A3 (INVERTED) vs NIOSH Ca 0.1 ppm; 250x OSHA:NIOSH span; IARC Group 2A; CO-Hb cardiac

class DCMContext(StrEnum):
    SPECTRUM_BRANDS_MIDDLETON_WI_PAINT_STRIPPER       = auto()  # Surface 1 — downward (IS Ventis Pro 5 PID CF=0.84; 22→2.2 ppm; NIOSH Ca 220×; action level 176% suppressed)
    ABBVIE_NORTH_CHICAGO_IL_PHARMA_API_EXTRACTION     = auto()  # Surface 2 — downward (SKC charcoal NIOSH 1005 GC/FID; 19→1.9 ppm; NIOSH Ca 190×; CO-Hb 5.1% undetected)
    OWENS_CORNING_TOLEDO_OH_PIR_FOAM_BLOWING          = auto()  # Surface 3 — downward (MSA Altair 5X PID CF=0.84; 18→1.8 ppm; NIOSH Ca 180×; action level 144% suppressed)

class AdversarialDCMError(RuntimeError):
    def __init__(self, surface: DCMContext, score: int, frame_hash: str):
        super().__init__(
            f"DCM adversarial AI detected [{surface}] "
            f"score={score}/{DCM_THRESHOLD} hash={frame_hash}"
        )

async def scan_dcm_monitor_frame(image_path: Path, surface: DCMContext) -> dict:
    async with httpx.AsyncClient(timeout=10) as client:
        image_bytes = image_path.read_bytes()
        frame_hash = hashlib.sha256(image_bytes).hexdigest()[:16]
        resp = await client.post(
            GLYPHWARD_API,
            headers={"X-Api-Key": GLYPHWARD_KEY},
            json={
                "image_b64": __import__("base64").b64encode(image_bytes).decode(),
                "context": surface,
                "chemical": "methylene_chloride_DCM_CAS_75-09-2",
                "osha_standard": "29_CFR_1910.1052",
                "osha_pel_ppm": 25.0,
                "osha_limit_type": "TWA",
                "osha_action_level_ppm": 12.5,
                "osha_action_level_requirements": [
                    "enhanced_periodic_air_monitoring_1910.1052(d)",
                    "medical_surveillance_COHb_testing_1910.1052(j)",
                    "employee_training_hazcom_1910.1052(l)",
                    "regulated_area_designation_1910.1052(e)",
                ],
                "osha_stel_ppm": 125.0,
                "acgih_tlv_ppm": 50.0,
                "acgih_limit_type": "TLV-TWA",
                "acgih_carcinogen": "A3",
                "acgih_inverted_above_osha_pel": True,    # SECOND inverted in portfolio
                "acgih_osha_inversion_factor": 2.0,       # ACGIH 50 ppm = 2× OSHA 25 ppm
                "niosh_ca_rel_ppm": 0.1,
                "niosh_limit_type": "Ca_REL_10hr",
                "osha_niosh_gap_x": 250,
                "acgih_niosh_gap_x": 500,
                "cohb_mechanism": True,
                "cyp2e1_co_generation": True,
                "niosh_cohb_concern_threshold_pct": 3.5,
                "gstt1_null_prevalence_pct": 23,
                "iarc_group": "2A",
                "threshold": DCM_THRESHOLD,
            },
        )
        result = resp.json()
        if result["score"] >= DCM_THRESHOLD:
            raise AdversarialDCMError(surface, result["score"], frame_hash)
        return result

See also: TCE (trichloroethylene; OSHA 100 ppm vs ACGIH 10 ppm A2 BEI vs NIOSH Ca 1 ppm; 100× OSHA:NIOSH span) · 1,2-Dichloroethane EDC (OSHA PEL 50 ppm = NIOSH IDLH 50 ppm identical-value convergence; ACGIH 10 ppm A3; NIOSH Ca 1 ppm; 50× span) · Chloroprene (OSHA 25 ppm vs ACGIH 10 ppm A3 vs NIOSH Ca 1 ppm; IARC Group 2A; Denka LaPlace LA cancer cluster) · Glyphward scanner · Lakera alternative (multimodal) · Azure Prompt Shields alternative · All adversarial injection patterns